Related Experiment Video
Updated: Sep 27, 2025
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
Published on: December 15, 2011
Injection of prototypic celiac anti-transglutaminase 2 antibodies in mice does not cause enteropathy
Christian B Lindstad1,2, M Fleur du Pré1,3, Jorunn Stamnaes1,2,3
1K.G. Jebsen Coeliac Disease Research Centre, University of Oslo, Oslo, Norway.
Background:
Celiac disease is an autoimmune enteropathy driven by dietary intake of gluten proteins. Typical histopathologic features are villous flattening, crypt hyperplasia and infiltration of inflammatory cells in the intestinal epithelium and lamina propria. The disease is hallmarked by the gluten-dependent production of autoantibodies targeting the enzyme transglutaminase 2 (TG2). While these antibodies are specific and sensitive diagnostic markers of the disease, a role in the development of the enteropathy has never been established.
Methods:
We addressed this question by injecting murine antibodies harboring the variable domains of a prototypic celiac anti-TG2 immunoglobulin into TG2-sufficient and TG2-deficient mice evaluating for celiac enteropathy.
Results:
We found no histopathologic abnormalities nor clinical signs of disease related to the injection of anti-TG2 IgG or IgA.
Conclusions:
Our findings do not support a direct role for secreted anti-TG2 antibodies in the development of the celiac enteropathy.
